There are four lines of evidence for or against a role of neuropeptides in epilepsy: Administration of a variety of opiate agonists into the ventricles or brain of animals produces a constellation of electrical and behavioral changes, seemingly receptor-specific, both sensitive to the specific opiate antagonist naloxone as well as certain anticonvulsant drugs. The primary reservation concerning these data in terms of their relevance to epilepsy regards the fact that the peptides are exogenously administered in relatively high doses. Hence, these data may reflect neurotoxic effects of peptides rather than physiologic function. A variety of opiate agonists are anticonvulsant and naloxone shortens the postictal state in some experimental seizure models. One could attempt to reconcile these data with those in No. 1 by hypothesizing that the spikes and behavioral changes examined in the latter experimental parodynes represented a sort of isolated model of the postictal state. Naloxone has little effect in clinical epilepsy. These data are far from conclusive for two reasons. First, few patients have been studied. Second, because of the issue of opiate receptor heterogeneity and the high doses of naloxone needed experimentally to block non-mu opiate effects, the doses of naloxone used clinically to date are too low to rule out possible delta- or epsilon-mediated effects. The negative clinical data are illustrative of the dangers and difficulties of extrapolating data generated in animal models of seizures to the human condition. ACTH, a peptide that is derived from the same precursor molecule as beta-endorphin, is clearly an effective anticonvulsant in certain childhood seizure states. However, whether this is due to a direct or indirect (that is, cortisol) effect on brain is far from clear. Paradoxically, in contradistinction to other data concerning pro- and anticonvulsant properties of various opioid peptides, there is no animal model of infantile spasms to help resolve this important question.
关于神经肽在癫痫中所起作用,有四条支持或反对的证据:向动物脑室或脑内注射多种阿片类激动剂会产生一系列电活动和行为变化,这些变化似乎具有受体特异性,对特定的阿片类拮抗剂纳洛酮以及某些抗惊厥药物均敏感。就这些数据与癫痫的相关性而言,主要的保留意见在于肽是以外源性相对高剂量给药的。因此,这些数据可能反映的是肽的神经毒性作用而非生理功能。多种阿片类激动剂具有抗惊厥作用,并且在一些实验性癫痫模型中,纳洛酮可缩短发作后期。有人可能试图通过假设在后者实验模拟中检测到的尖峰和行为变化代表了发作后期的一种孤立模型,来使这些数据与第一条中的数据相协调。纳洛酮在临床癫痫中作用甚微。这些数据远非结论性的,原因有二。其一,研究的患者很少。其二,由于阿片受体异质性问题以及实验中阻断非μ阿片效应所需的纳洛酮高剂量,迄今为止临床使用的纳洛酮剂量过低,无法排除可能由δ或ε介导的效应。负面的临床数据说明了将癫痫动物模型中产生的数据外推至人类情况的危险性和困难。促肾上腺皮质激素(ACTH)是一种与β - 内啡肽源自同一前体分子的肽,在某些儿童癫痫状态下显然是一种有效的抗惊厥剂。然而,这是对大脑的直接作用还是间接作用(即通过皮质醇)尚不清楚。矛盾的是,与关于各种阿片肽的促惊厥和抗惊厥特性的其他数据相反,没有婴儿痉挛症的动物模型来帮助解决这个重要问题。